FDA
23rd July 2018

FDA Advisory Committee Unanimously Supports SIGA Technologies’ Tecovirimat

On May 1st, 2018 the Antimicrobial Drugs Advisory Committee reviewed the new drug application (NDA) 208627 for SIGA Technologies’ tecovirimat.

FDA Advisory Committee Unanimously Supports SIGA Technologies’ Tecovirimat

On May 1st, 2018 the Antimicrobial Drugs Advisory Committee reviewed the new drug application (NDA) 208627 for SIGA Technologies’ tecovirimat, proposed for the treatment of smallpox caused by the variola virus, in pediatrics and adults.  The drug inhibits the production of extracellular viral forms responsible for the spread of infection within the body. Although smallpox was considered eradicated in 1980 due to widespread vaccination, the US population may currently be susceptible due to the halt in routine vaccinations. In the case of an outbreak, tecovirimat, may be useful in preventing the spread of the virus.

SIGA discussed the potential to use smallpox as a bioweapon and the importance of having a treatment to combat it. The proposed dosing for the oral tablet was 600 mg, twice daily, to achieve safe and efficacious levels in humans.

Efficacy trials were conducted in animals as a substitute for human clinical trials. Six animal model studies were used to assess efficacy, 4 in non-human primates (NHP)s and 2 in rabbits. All cases discussed showed nearly complete protection from death and reduced morbidity. Twelve human safety studies were conducted and showed that tecovirimat was generally well-tolerated. Adverse events were reported  in 37% of Tecovirimat patients and 33% in the control group, with the most common AEs being headaches, nausea and abdominal pain.

Panelists were asked to vote on whether the risk-benefit profile of tecovirimat supports its use for the treatment of human smallpox. The panel unanimously voted  towards approval of tecovirimat (17 Yes, No). The committee praised the appropriate use of the animal rule by the sponsor. Members noted that tecovirimat fills an unmet need – an effective drug for a disease to which there was no currently approved treatment.

The agency is not obligated to follow its panel’s recommendation, but normally does so. On July 13th  the FDA approved TPOXX (tecovirimat) as the first drug indicated for smallpox.

ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

This post was authored by Sami Mourad. Sami is a summer intern at ISS and a 3rd year pharmacy student at the Rutgers University Ernest Mario School of Pharmacy

 

 

Do you have an upcoming Advisory Committee Meeting?

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us